Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive non-squamous non–small-cell lung cancer …

N Yamamoto, T Seto, M Nishio, K Goto, I Okamoto… - 2018 - ascopubs.org
9007 Background: In JO25567 (Clinical trials registry number. JapicCTI-111390), EB
significantly prolonged progression-free survival (PFS) in patients with NSCLC with …
被引用次数：86 相关文章

[引用][C] Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive non-squamous non–small-cell lung …

N Yamamoto, T Seto, M Nishio, K Goto… - Journal of Clinical …, 2018 - cir.nii.ac.jp
Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced
EGFR mutation–positive non-squamous non–small-cell lung cancer (NSCLC): Survival …